Bentham Science Logo
Journal Cover

Track Your Manuscript:

Current Cancer Drug Targets

Volume 22, 11 Issues, 2022
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access

Aims & Scope

Current Cancer Drug Targets aims to cover all the latest and outstanding developments in full spectrum of cancer drug discovery and development, including but not limited to cellular and molecular biology, genomics, proteomics, metabolomics, medicinal chemistry, pharmacology, toxicology, and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.

Current Cancer Drug Targets publishes original research articles, letters/commentary/perspectives, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer.

As the discovery, identification, characterization and validation of novel drug targets for human anticancer drug discovery continues to grow, this journal has become essential reading for all biomedical and pharmaceutical scientists involved in drug discovery and development. Its scope covers publications related to prevention, diagnosis and treatment of all types of human cancers in various of basic and translational researches, including cancer etiology, signal transduction, biomarker, chemotherapy, hormone therapy, gene therapy, immunotherapy, radiotherapy, immunotherapy and combination therapy, stem cell, tumor environment, metabolism emphasizing on advanced mechanistic investigations.

Current Cancer Drug Targets


Volume 22


Number 7

Research Article

Modulation of ATP8B1 Gene Expression in Colorectal Cancer Cells Suggest its Role as a Tumor Suppressor

, 22(7): 577 - 590

Saleh Althenayyan, Amal AlGhamdi, Mohammed H. AlMuhanna, Esra Hawsa, Dalal Aldeghaither, Jahangir Iqbal, Sameer Mohammad and Mohammad A. Aziz*

DOI: 10.2174/1568009622666220517092340

Research Article

Silencing of FANCI Promotes DNA Damage and Sensitizes Ovarian Cancer Cells to Carboplatin

, 22(7): 591 - 602

Yuqing Li, Yanan Zhang, Qi Yang, Xuantong Zhou, Yuanyuan Guo, Fang Ding, Zhihua Liu and Aiping Luo*

DOI: 10.2174/1568009622666220331091709

Current Cancer Drug Targets, Volume 22 (2022) - Number 9

This issue is in progress but contains articles that are final and fully citable.

Current Cancer Drug Targets, Volume 22 (2022) - Number 8

This issue is in progress but contains articles that are final and fully citable.

Abstracts Ahead of Print

Epigallocatechin-3-gallate induced HepG2 cells apoptosis through ROS-Mediated AKT /JNK and p53 signaling pathway..

Yutao Guan, Qianlong Wu, Miaomiao Li, Danyang Chen, Jingyao Su, Liandong Zuo*, Bing Zhu* and Yinghua Li*

DOI: 10.2174/1568009622666220705101642
View Abstract

Dextran Sulfate Inhibits Angiogenesis and Invasion of Gastric Cancer by Interfering with M2-type Macrophages Polarization

Jiaxin Guo*, Zhaojun Li, Qian Ma, Mengqi Li, Yuan Zhao, Bing Li, Yuejia Tao, Yuanyi Xu* and Yunning Huang*

DOI: 10.2174/1568009622666220705095403
View Abstract

Recent Progress in Histone deacetylase (HDAC) 1 Inhibitors as Anticancer Agent.

Preeti Patel*, Simranpreet K. Wahan, S. Vishakha, Balak Das Kurmi, Ghanshyam Das Gupta, Harish Rajak and Vivek Asati

DOI: 10.2174/1568009622666220624090542
View Abstract

Cucurbitacin D inhibits the proliferation of HepG2 cells and induces apoptosis by modulating JAK/STAT3, PI3K/Akt/mTOR and MAPK signaling pathways

Muhammed Mehdi Üremiş, Nuray Üremiş, Emir Tosun, Merve Durhan, Yılmaz Çiğremiş, Ahmet Baysar and Yusuf Türköz*

DOI: 10.2174/1568009622666220623141158
View Abstract

Targeting the transforming growth factor-beta signaling pathway in the treatment of gynecologic cancer

Sadaf Ghanaatgar-Kasbi*, Farzaneh Pouya*, Negar Khoshghamat*, Ghazaleh Ghorbannezhad*, Majid Khazaei*, Malihe Hasanzadeh, Gordon A Ferns and Amir Avan*

DOI: 10.2174/1568009622666220623115614
View Abstract

Published Contents

Editor's Choice

Metastatic Breast Cancer, Organotropism and Therapeutics: A Review

, 2021; 21(10): 813 - 828

Ajaz Ahmad Waza*, Najeebul Tarfeen, Sabhiya Majid, Yasmeena Hassan, Rashid Mir, Mohd Younis Rather and Naseer Ue Din Shah

DOI: 10.2174/1568009621666210806094410

Cholangiocarcinoma Therapeutics: An Update

, 2021; 21(6): 457 - 475

Mai Ly Thi Nguyen, Nguyen Linh Toan, Maria Bozko, Khac Cuong Bui* and Przemyslaw Bozko*

DOI: 10.2174/1568009621666210204152028

PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance

, 2021; 21(4): 306 - 325

Sarah F. Giardina*, Elena Valdambrini, J. David Warren and Francis Barany

DOI: 10.2174/1568009621666210203110857

Novel MicroRNA Binding Site SNPs and the Risk of Clear Cell Renal Cell Carcinoma (ccRCC): A Case-Control Study

, 2021; 21(3): 203 - 212

Irina R. Gilyazova, Narasimha M. Beeraka, Elizaveta A. Klimentova, Kirill V. Bulygin, Vladimir N. Nikolenko, Adel A. Izmailov, Gulshat R. Gilyazova, Valentin N. Pavlov, Elsa K. Khusnutdinova, Siva G. Somasundaram, Cecil E. Kirkland and Gjumrakch Aliev*

DOI: 10.2174/1568009620666201120151226

Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells

, 2021; 21(2): 117 - 131

Wenjun Wang, Ling Bai, Dongsheng Xu, Wei Li and Jiuwei Cui*

DOI: 10.2174/1568009620666200504111914

C-Myc Signaling Pathway in Treatment and Prevention of Brain Tumors

, 2021; 21(1): 2 - 20

Milad Ashrafizadeh, Ali Zarabi, Kiavash Hushmandi, Ebrahim Rahmani Moghadam, Farid Hashemi, Salman Daneshi, Fardin Hashemi, Shima Tavakol, Reza Mohammadinejad, Masoud Najafi*, Namrata Dudha and Manoj Garg*

DOI: 10.2174/1568009620666201016121005

Open Access Articles

Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy

, 2022; 22(6): 530 - 536

Xue Wang, Nanlin Hu, Lina Cui, Yiran Si, Jian Yue, Fangchao Zheng, Yikun Kang and Peng Yuan*

Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators

, 2021; 21(4): 353 - 359

Stefanie Rauscher, Richard Greil and Roland Geisberger*

Tumor Penetrating Peptide-Functionalized Tenascin-C Antibody for Glioblastoma Targeting

, 2021; 21(1): 70 - 79

Prakash Lingasamy, Anett-Hildegard Laarmann and Tambet Teesalu *

Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL

, 2020; 20(10): 811 - 817

Sven Nilsson, Alexander Stein, Christian Rolfo, Anne L. Kranich, Julia Mann, Konstantinos Papadimitriou, Susann Theile, Stefanie Amberg and Carsten Bokemeyer*

The Roles of Alternative Splicing in Tumor-immune Cell Interactions

, 2020; 20(10): 729 - 740

Yue Wang, Honglei Zhang*, Baowei Jiao*, Jianyun Nie*, Xiyin Li, Wenhuan Wang and Hairui Wang

Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer

, 2019; 19(1): 74 - 80

Peng Liu, Hailin Tang, Jiali Wu, Xingsheng Qiu, Yanan Kong, Lijuan Zhang, Xinhua Xie* and Xiangsheng Xiao*

Role of MicroRNAs in Treatment Response in Prostate Cancer

, 2018; 18(10): 929 - 944

Anshuli Razdan, Paul de Souza* and Tara Laurine Roberts

Noxa: Role in Cancer Pathogenesis and Treatment

, 2018; 18(10): 914 - 928

Rami Z. Morsi, Rouba Hage-Sleiman, Hadile Kobeissy and Ghassan Dbaibo*

Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer

, 2016; 16(4): 346 - 356

Xue-Qing Hu, Yang Sun, Eric Lau, Ming Zhao and Shi-Bing Su

Most Cited Articles

Review Article

Polyploid giant cancer cells (PGCCs): The evil roots of cancer

, 2019; 19(5): 360-367.

Junsong Chen, Na Niu, Jing Zhang, Lisha Qi , Weiwei Shen , Krishna Vanaja Donkena, Zhenqing Feng and Jinsong Liu *

DOI: 10.2174/1568009618666180703154233

Review Article

Old and new approaches to target the hsp90 chaperone

, 2020; 20(4): 253-270.

Jackee Sanchez, Trever R. Carter, Mark S. Cohen* and Brian S.J. Blagg

DOI: 10.2174/1568009619666191202101330

Review Article

Resveratrol as an adjuvant for normal tissues protection and tumor sensitization

, 2020; 20(2): 130-145.

Keywan Mortezaee, Masoud Najafi*, Bagher Farhood*, Amirhossein Ahmadi*, Dheyauldeen Shabeeb and Ahmed E. Musa

DOI: 10.2174/1568009619666191019143539

Review Article

HSF1 as a cancer biomarker and therapeutic target

, 2019; 19(7): 515-524.

Richard L. Carpenter* and Yesim Gokmen-Polar

DOI: 10.2174/1568009618666181018162117

Review Article

Glycolysis inhibition as a strategy for hepatocellular carcinoma treatment?

, 2019; 19(1): 26-40.

A.P. Alves, A.C. Mamede, M.G. Alves, P.F. Oliveira, S.M. Rocha, M.F. Botelho and C.J. Maia*

DOI: 10.2174/1568009618666180430144441

Review Article

The RNA binding protein hur: A promising drug target for anticancer therapy

, 2019; 19(5): 382-399.

Mingxia Wu, Christy W.S. Tong, Wei Yan, Kenneth K.W. To* and William C.S. Cho*

DOI: 10.2174/1568009618666181031145953

Review Article

Mesoporous silica nanoparticles as a prospective and promising approach for drug delivery and biomedical applications

, 2019; 19(4): 285-295.

Xiaohui Pu, Jia Li, Peng Qiao, Mengmeng Li, Haiyan Wang, Lanlan Zong*, Qi Yuan and Shaofeng Duan*

DOI: 10.2174/1568009619666181206114904

Research Article

Interactions of vascular endothelial growth factor and p53 with mir-195 in thyroid carcinoma: Possible therapeutic targets in aggressive thyroid cancers

, 2019; 19(7): 561-570.

Hamidreza Maroof , Soussan Irani , Armin Arianna, Jelena Vider, Vinod Gopalan and Alfred King-yin Lam *

DOI: 10.2174/1568009618666180628154727

Research Article

c-Myc inhibitor 10074-G5 induces murine and human hematopoietic stem and progenitor cell expansion and HDR modulator Rad51 expression

, 2019; 19(6): 479-494.

Merve Aksoz, Esra Albayrak, Galip Servet Aslan, Raife Dilek Turan, Lamia Yazgi Alyazici, Pınar Siyah, Emre Can Tuysuz, Serli Canikyan, Dogacan Yucel, Neslihan Meric, Zafer Gulbas, Fikrettin Sahin and Fatih Kocabas*

DOI: 10.2174/1568009618666180905100608

Review Article

Ursolic acid in cancer treatment and metastatic chemoprevention: From synthesized derivatives to nanoformulations in preclinical studies

, 2019; 19(4): 245-256.

Junjie Zou, Juanfang Lin, Chao Li, Ruirui Zhao, Lulu Fan, Jesse Yu and Jingwei Shao*

DOI: 10.2174/1568009618666181016145940

Review Article

Focal adhesion kinase in ovarian cancer: A potential therapeutic target for platinum and taxane-resistant tumors

, 2019; 19(3): 179-188.

Arkene Levy*, Khalid Alhazzani, Priya Dondapati, Ali Alaseem, Khadijah Cheema, Keerthi Thallapureddy, Paramjot Kaur, Saad Alobid and Appu Rathinavelu

DOI: 10.2174/1568009618666180706165222

Review Article

COVID-19 pandemic: Experiences in China and implications for its prevention and treatment worldwide

, 2020; 20(6): 410-416.

Ning-Ning Liu*, Jing-Cong Tan, Jingquan Li, Shenghui Li*, Yong Cai* and Hui Wang*

DOI: 10.2174/1568009620666200414151419

Most Accessed Articles

CDK-associated Cullin 1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Human Glioblastoma

, 2021; 21(10): 870-880.

Xiaohua Zhang, Tianying Zhang, Xiaojuan Han, Zhongying Qiu, Jianghong Cheng, Xingchun Gao and Xingchun Gou*

DOI: 10.2174/1568009621666210602164225

Role of ZEB Family Members in Proliferation, Metastasis, and Chemoresistance of Prostate Cancer Cells: Revealing Signaling Networks

, 2021; 21(9): 749-767.

Leyla soleymani, Ali Zarrabi, Farid Hashemi, Fardin Hashemi, Amirhossein Zabolian, Seyed Mohammad Banihashemi, Shirin Sabouhi Moghadam, Kiavash Hushmandi, Saeed Samarghandian, Milad Ashrafizadeh* and Haroon Khan*

DOI: 10.2174/1568009621666210601114631

Role of Exosomes in Breast Cancer Management: Evidence-Based Review

, 2021; 21(8): 666-675.

Razan B. Al-Humaidi, Bahgat Fayed, Suleiman I. Sharif, Ayman Noreddin and Sameh S.M. Soliman*

DOI: 10.2174/1568009621666210601115707

The Clinical Application of Circulating Tumor Cells and DNAs as Prognostic and Predictive Biomarkers in Gastrointestinal Cancer

, 2021; 21(8): 676-688.

Sara Memarpour*, Ghazaleh Khalili-Tanha*, Awa Alizadeh Ghannad, Masoud Sharifian Razavi, Mona Joudi, Marjan Joodi, Gordon A. Ferns, Seyed Mahdi Hassanian, Majid Khazaei and Amir Avan*

DOI: 10.2174/1568009621666210311090531

DDX39B Predicts Poor Survival and Associated with Clinical Benefit of Anti-PD-L1 Therapy in ccRCC

, 2021; 21(10): 849-859.

Jinhuan Wei, Jun Lu, Yun Cao, Gaosheng Yao, Yong Huang, Hongwei Zhao, Yihui Pan, Zihao Feng, Zhenhua Chen, Wei Chen, Junhang Luo* and Jiazheng Cao*

DOI: 10.2174/1568009621666210811115054

Crosstalk of Long Non-coding RNAs and EMT: Searching the Missing Pieces of an Incomplete Puzzle for Lung Cancer Therapy

, 2021; 21(8): 640-665.

Milad Ashrafizadeh, Md Shahinozzaman, Sima Orouei, Vahideh Zarrin, Kiavash Hushmandi, Farid Hashemi, Anuj Kumar, Saeed Samarghandian, Masoud Najafi* and Ali Zarrabi*

DOI: 10.2174/1568009621666210203110305

MiR-129-5p Promotes Radio-sensitivity of NSCLC Cells by Targeting SOX4 and RUNX1

, 2021; 21(8): 702-712.

Tongqing Xue, Gang Yin, Weixuan Yang, Xiaoyu Chen, Cheng Liu, Weixi Yang* and Jun Zhu*

DOI: 10.2174/1568009621666210415094350


Ruiwen Zhang
Center for Drug Discovery
University of Houston
Houston, TX
View Full Editorial Board

COPE Compliant

Cope Logo

Related Journals

Related eBooks

eBooks Catalog